Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III sirolimus trial in inclusion body myositis
ACTRN12620001226998Phase 3Recruiting
- Sponsor
- Perron Institute for Neurological and Translational Science
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in inclusion body myositis (IBM) comparing Sirolimus with Placebo (2 arms). Primary endpoint: Change in IBM Functional Rating Scale. Started Jun 2022; status: recruiting.
02
Drugs
sirolimus
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on ACTRN12620001226998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001226998.